SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indrayani Biotech informs about outcome of board meeting

15 Nov 2024 Evaluate

With reference to its intimation letter dated November 11, 2024 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Indrayani Biotech has informed that at the meeting of Board of Directors held on Thursday, November 14, 2024, the Directors have approved the following: Unaudited Financial Results (Standalone and Consolidated) with the Limited Review Report for the quarter and half year ended September 30, 2024 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements} Regulations, 2015. The statutory auditors have reviewed the financial results and given unmodified opinion. (Results are provided as Annexure). The necessary arrangements are in place to publish the unaudited financial results in the newspapers. The said financial results will also be available on company’s website www.indrayani.com and also on BSE website www.bseindia.com. The Board has considered the issue of fully paid-up equity shares by way of a rights issue to the existing shareholders of the Company in accordance with the provisions of Companies Act, 2013 and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other applicable laws for an amount not exceeding Rs.49.90 Crores. iii. Further, the Board has constituted a Rights Issue Committee and authorized its members to decide on the terms and conditions of the Issue, including but not limited to, the final Issue size/amount, rights entitlement ratio, the issue price, record date, timing of the Rights Issue, approval of draft letter of offer; appointment of intermediaries, if required; allotment of shares and other related matters. The meeting commenced at 03:00 pm and concluded at 11:40 pm.

The above information is a part of company’s filings submitted to BSE.

Indrayani Biotech Share Price

12.08 0.00 (0.00%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Grasim Industries 2777.75
DCM Shriram 1200.00
3M India 31548.55
Hindustan Foods 496.85
Balmer Lawrie & Co 177.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×